{
    "clinical_study": {
        "@rank": "92349", 
        "acronym": "RESUME", 
        "arm_group": {
            "arm_group_label": "Non-Interventional Study"
        }, 
        "brief_summary": {
            "textblock": "Retrospective and prospective study in mRCC patients treated with sutent in first line and\n      rechallenged by Sutent in 3rd and 4th line."
        }, 
        "brief_title": "Sutent Rechallenge In mRCC Patients", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Metastatic Renal Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Renal Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "A sample size of n = 40 patients will allow to estimate of the median PFS with a precision\n      around 1.8 months  (based on data from Rini et al.) This retrospective and prospective study\n      is designed to estimate the effect of Sutent rechallenge.\n\n      The PFS (estimated from Kaplan-Meier estimate)  will be the primary endpoints. In addition,\n      the effects of sunitinib at the 2 periods of treatment (i.e. first line sunitinib vs.\n      rechallenge) will be compared by Wilcoxon signed-rank test for PFS values and by McNemar\n      test for overall response rate (ORR)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically documented metastatic RCC containing predominantly clear cell\n             component.\n\n          -  Previously received sunitinib in first line, 2 or more antitumor therapies\n             subsequently and then received sunitinib for a second time.\n\n          -  At least 1 cycle of sunitinib rechallenge (1 cycle= 4 weeks on/2 weeks off).\n\n          -  At least 1 measurable lesion that can be accurately measured in at least 1 dimension\n             with the longest diameter (LD) \u00b3 10 mm when measured by spiral computerized\n             tomography (CT) (5-mm slice thickness contiguous) or \u00b3 20 mm when measured by\n             conventional CT (10-mm slice thickness contiguous). The lesion must be \u00b3 2 times the\n             size of the slice thickness per RECIST criteria.\n\n          -  Life expectancy of at least 3 months.\n\n        Exclusion Criteria:\n\n          -  Patient who didn't receive Sunitinib in first line.\n\n          -  Patient who received less than one line of treatment ."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "mRCC patients treated with sunitinib in first line and rechallenged with sunitinib in 3rd\n        and 4th line"
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01827254", 
            "org_study_id": "A6181211"
        }, 
        "intervention": {
            "arm_group_label": "Non-Interventional Study", 
            "description": "Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line", 
            "intervention_name": "sunitinib: observational study", 
            "intervention_type": "Other", 
            "other_name": "sunitinib 50 mg 4/2"
        }, 
        "intervention_browse": {
            "mesh_term": "Sunitinib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "sutent rechallenge", 
        "lastchanged_date": "May 22, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6181211&StudyName=Sutent%20Rechallenge%20In%20mRCC%20Patients"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "state": "Cedex 5", 
                        "zip": "13335"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Grenoble", 
                        "country": "France", 
                        "state": "Cedex 9", 
                        "zip": "38043"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49100"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bordeaux Cedex", 
                        "country": "France", 
                        "zip": "33075"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cabestany", 
                        "country": "France", 
                        "zip": "66330"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lille Cedex", 
                        "country": "France", 
                        "zip": "59042"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Limoges Cedex", 
                        "country": "France", 
                        "zip": "87042"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lyon Cedex 08", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille Cedex", 
                        "country": "France", 
                        "zip": "13385"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marseille Cedex 9", 
                        "country": "France", 
                        "zip": "13273 Cedex 9"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 15", 
                        "country": "France", 
                        "zip": "75908"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35042"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "ROUEN Cedex", 
                        "country": "France", 
                        "zip": "76031"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Priest en Jarez Cedex", 
                        "country": "France", 
                        "zip": "42271"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Herblain Cedex", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31000"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vandoeuvre les Nancy", 
                        "country": "France", 
                        "zip": "54511"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "Evaluate The Efficacy Of Sunitinib Rechallenge In mRCC Patients Treated With Sutent In First Line And Rechallenged In 3rd And 4th Line", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: French Data Protection Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Median time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.", 
            "measure": "Progression-Free Survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline up to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01827254"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Percentage of participants with OR based assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed remission are those with repeat bone marrow showing less than 5 percent (%) myeloblasts with normal maturation of all cell lines and absolute values of the peripheral blood lasting at least 2 months. PR are those with all CR criteria except at least 50% decrease in the blasts over the pretreatment.", 
            "measure": "Percentage of Participants With Objective Response", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}